IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v14y1998i6p653-669.html
   My bibliography  Save this article

Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction

Author

Listed:
  • Peter Schädlich
  • Eduard Huppertz
  • Josef Brecht

Abstract

Objective: Data from the Acute Infarction Ramipril Efficacy (AIRE) study were used in a cost-effectiveness analysis to determine the incremental cost per lifeyear gained (LYG) when the ACE inhibitor ramipril was added to conventional treatment in patients with heart failure after acute myocardial infarction. In the AIRE trial, the addition of ramipril significantly lowered rates of total mortality and rehospitalisation due to heart failure. Design and Setting: The cost-effectiveness analysis was conducted from the perspective of the Statutory Health Insurance (SHI) provider in Germany. A modelling approach was used which was based on secondary analysis of existing data, and costs were those incurred by SHI (i.e. expenses of SHI). In the base-case analysis, average case-related expenses of SHI were applied and LYG were quantified by the method of Kaplan and Meier. Main outcome measures and results: The incremental cost-effectiveness ratios of ramipril varied between 2500 and 8300 deutschmarks (DM) per LYG (1993 values for inpatient and 1995 values for outpatient treatment; DM1 » $US0.70), according to the treatment periods of 3.8 years and 1 year, respectively. In the sensitivity analysis, the robustness of the model and its results was shown when the extent of influence of different model variables on the base-case results was investigated. First, survival probability and LYG were estimated according to the Weibull method. Second, the dependency of the target variable (i.e. incremental cost per LYG) on random variables was described in a simulation. Third, the influence of the model variables on the target variable was quantified using a deterministic model. The variance of the target variable was broad and the hospitalisation impact of adding ramipril to conventional treatment was an independent variable with much greater influence on the target variable than the parameter of clinical effectiveness, i.e. the number of LYG. Conclusion: Results of this evaluation showed that ramipril has a favourable incremental cost-effectiveness ratio for the treatment of heart failure in post myocardial infarction patients and can be considered an economical therapeutic agent from the perspective of SHI (third-party payer) in Germany. Copyright Adis International limited 1998

Suggested Citation

  • Peter Schädlich & Eduard Huppertz & Josef Brecht, 1998. "Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction," PharmacoEconomics, Springer, vol. 14(6), pages 653-669, December.
  • Handle: RePEc:spr:pharme:v:14:y:1998:i:6:p:653-669
    DOI: 10.2165/00019053-199814060-00006
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-199814060-00006
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.2165/00019053-199814060-00006?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Peter Schädlich & Michael Kentsch & Manfred Weber & Wolfgang Kämmerer & Josef Brecht & Vijay Nadipelli & Eduard Huppertz, 2006. "Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients," PharmacoEconomics, Springer, vol. 24(6), pages 571-591, June.
    2. Peter Schädlich & Josef Brecht & Massimo Brunetti & Eva Pagano & Badrudin Rangoonwala & Eduard Huppertz, 2001. "Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension," PharmacoEconomics, Springer, vol. 19(5), pages 497-512, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:14:y:1998:i:6:p:653-669. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.